TABLE 1.

GMVs of IgG antibody to PT and FHA in convalescent-phase sera from previous recipients of JNIH-6, JNIH-7, or placebo who had pertussis due to B. pertussis infection

Group (no. of subjects)GMV, EU/ml (95% CIa)
PTFHA
JNIH-6 (25)107.2 (74.7-153.8)87.1 (60.7-125.0)b
JNIH-7 (33)131.8 (90.6-191.9)12.9 (8.9-18.6)c
Placebo (49)195.0 (137.2-276.9)21.9 (14.7-32.5)
  • a 95% CI, 95% confidence interval.

  • b JNIH-6 versus JNIH-7, P < 0.0001.

  • c JNIH-7 versus placebo, P = 0.23.